Entrepreneur Marc Beer returned to the business world after his wife's death by taking the helm of Aegerion Pharmaceuticals, which offers a drug used to treat a rare genetic condition that can cause heart attacks in patients before they turn 20. Investors initially had rejected the drug, but now the company's shares are up 160% over the past year. Within the next few years, 767 patients are expected to be on the drug, called Juxtapid.

Full Story:

Related Summaries